Division of Cardiology, Department of Medicine, Temple University Hospital, Lewis Katz School of Medicine, Philadelphia, Pa.
Division of Cardiology, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pa.
J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):627-634.e2. doi: 10.1016/j.jvsv.2020.08.029. Epub 2020 Sep 10.
Although acute intracranial hemorrhage (ICH) is a rare complication of catheter-directed thrombolysis (CDT), it remains a major concern associated with the use of CDT. The incidence and clinical predictors of developing ICH in the setting of CDT are not known.
The National Inpatient Sample database was used to identify all patients with proximal lower extremity or caval deep vein thrombosis (DVT) from January 2005 to December 2013 in the United States. Multivariate logistic regression was performed to identify the clinical predictors of ICH between patients with DVT who had received anticoagulation therapy alone and those who had been treated with CDT plus anticoagulation therapy.
Of 138,049 patients with proximal lower extremity or caval DVT, 7119 (5.2%) had received anticoagulation therapy and CDT. Of the patients treated with anticoagulation alone, ICH had occurred in 0.2% compared with 0.7% for those treated with CDT (P < .01). The independent predictors of ICH in the CDT cohort were a history of stroke (odds ratio [OR], 19.4; 95% confidence interval [CI], 8.8-42.8; P < .01), chronic kidney disease (OR, 2.2; 95% CI, 1.1-4.7; P = .03), age >74 years (OR, 2.2; 95% CI, 1.2-4.3; P = .02), male sex (OR, 1.8; 95% CI, 1.01-3.3; P = .048). Of those patients treated with anticoagulation alone, the risk factors for the development of ICH were a history of stroke, hospital teaching status, and age >74 years.
The results from the present nationwide observational study showed that of patients with DVT treated with CDT, the independent predictors for developing ICH were a history of stroke, chronic kidney disease, male sex, and age >74 years.
尽管急性颅内出血(ICH)是导管定向溶栓(CDT)的罕见并发症,但它仍然是与 CDT 使用相关的主要关注点。ICH 在 CDT 治疗中的发生频率和临床预测因素尚不清楚。
本研究使用美国国家住院患者样本数据库,于 2005 年 1 月至 2013 年 12 月期间,确定所有近端下肢或腔静脉深静脉血栓形成(DVT)患者。采用多变量逻辑回归分析,确定仅接受抗凝治疗与接受 CDT 联合抗凝治疗的 DVT 患者之间 ICH 的临床预测因素。
在 138049 例近端下肢或腔静脉 DVT 患者中,7119 例(5.2%)接受了抗凝治疗和 CDT。在仅接受抗凝治疗的患者中,ICH 的发生率为 0.2%,而接受 CDT 治疗的患者中 ICH 的发生率为 0.7%(P<0.01)。CDT 组中 ICH 的独立预测因素为既往卒中史(比值比[OR],19.4;95%置信区间[CI],8.8-42.8;P<0.01)、慢性肾脏病(OR,2.2;95%CI,1.1-4.7;P=0.03)、年龄>74 岁(OR,2.2;95%CI,1.2-4.3;P=0.02)、男性(OR,1.8;95%CI,1.01-3.3;P=0.048)。在仅接受抗凝治疗的患者中,ICH 发生的危险因素为既往卒中史、医院教学地位和年龄>74 岁。
本项全国性观察性研究结果表明,在接受 CDT 治疗的 DVT 患者中,ICH 的独立预测因素为既往卒中史、慢性肾脏病、男性和年龄>74 岁。